Suchergebnisse

Background: It is now widely acknowledged that depression is accompanied by major deficits in social functioning. However, the course of this dysfunction and its relationship with depressive symptoms in the long term is less understood. Methods: The Group for Longitudinal Affective Disorders Study (GLADS) in Japan has conducted a 10-year prospective, serial follow-up of a cohort of mood disorder patients starting treatment for their index episode. The vicissitudes of the social adjustment of patients with major depression were analyzed using the standardized instrument (Social Adjustment Scale — Self-Report) and in conjunction with the measurement of depressive severity (Centre for Epidemiologic Studies Depression). Results: The results showed: (i) psychiatric patients with major depression commencing treatment showed moderate to extremely large social dysfunction at baseline; (ii) this dysfunction declined rapidly in the first six months of treatment but then levelled off and showed fluctuating patterns up to 10 years of follow-up; (iii) the degree of dysfunction varied from domain to domain, most notable in Work and least notable in Economy subscales; and (iv) the influence of persistent depression also varied from domain to domain, stronger in Housework and Leisure and weakest in Work spheres. Conclusion: Future studies of social functioning in depression need to differentiate its various aspects.

AbstractCyclic anthraquinone derivatives (cAQs), which link two side chains of 1,5-disubstituted anthraquinone as a threading DNA intercalator, have been developed as G-quartet (G4) DNA-specific ligands. Among the cAQs, cAQ-mBen linked through the 1,3-position of benzene had the strongest affinity for G4 recognition and stabilization in vitro and was confirmed to bind to the G4 structure in vivo, selectively inhibiting cancer cell proliferation in correlation with telomerase expression levels and triggering cell apoptosis. RNA-sequencing analysis further indicated that differentially expressed genes regulated by cAQ-mBen were profiled with more potential quadruplex-forming sequences. In the treatment of the tumor-bearing mouse model, cAQ-mBen could effectively reduce tumor tissue and had less adverse effects on healthy tissue. These results suggest that cAQ-mBen can be a potential cancer therapeutic agent as a G4 binder.